SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-193328
Filing Date
2021-06-17
Accepted
2021-06-17 17:12:05
Documents
1
Period of Report
2021-06-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d124949d8k.htm 8-K 20280
  Complete submission text file 0001193125-21-193328.txt   21399
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 211025703
SIC: 2836 Biological Products, (No Diagnostic Substances)